THERESE: HFpEF and 2-year Mortality of COPD Patients
Study Details
Study Description
Brief Summary
This study was designed to assess potential relationship between heart failure with preserved ejection fraction and 2- year mortality of patients with chronic obstructive pulmonary disease
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Normal cardiac function Normal cardiac function |
Diagnostic Test: Cardiac function assessment
Echocardiography, cardiac enzymes analysis
|
Heart failure with reduced ejection fraction Heart failure with reduced ejection fraction |
Diagnostic Test: Cardiac function assessment
Echocardiography, cardiac enzymes analysis
|
Heart failure with preserved ejection fraction Heart failure with preserved ejection fraction |
Diagnostic Test: Cardiac function assessment
Echocardiography, cardiac enzymes analysis
|
Outcome Measures
Primary Outcome Measures
- Mortality [2 year]
Mortality of patients
Eligibility Criteria
Criteria
Inclusion Criteria:
Exacerbation of chronic obstructive pulmonary disease requiring hospitalization
Age 40 - 80 years
Performance status 0-1 according to Eastern Cooperative Oncology Group (ECOG)
Long acting beta agonist (LABA)/ long acting antimuscarinic (LAMA) bronchodilator treatment
Exclusion Criteria:
Presence of major heart valve dysfunction
Documented noncompliance with treatment
Presence of active malignancy
Body mass index > 40
Interstitial lung disease
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Frydek Mistek Hospital | Frýdek-Místek | Czechia | ||
2 | University Hospital Olomou | Olomouc | Czechia | 77900 |
Sponsors and Collaborators
- University Hospital Olomouc
Investigators
- Principal Investigator: Milan Sova, Ph.D., Department of Respiratory Medicine
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- THERESE